SANDUPHQPharmaceuticals
Sandu Pharmaceuticals, Inc — Cash Flow Statement
₹30.52
-6.58%
Sandu Pharmaceuticals, Inc Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.01 Cr | -0.67 Cr | -0.85 Cr | 0.11 Cr | — |
| Capital Expenditure | -0.94 Cr | -1.43 Cr | -1.07 Cr | -0.84 Cr | — |
| End Cash Position | 1.30 Cr | 1.00 Cr | 2.28 Cr | 0.94 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | 3000.00 | 1000.00 | — | — |
| Beginning Cash Position | 1.00 Cr | 2.28 Cr | 0.94 Cr | 4.53 Cr | — |
| Changes In Cash | 0.30 Cr | -1.27 Cr | 1.34 Cr | -3.59 Cr | — |
| Financing Cash Flow | -0.46 Cr | -0.72 Cr | 0.58 Cr | 0.93 Cr | — |
| Interest Paid Cff | -0.10 Cr | -0.06 Cr | -0.08 Cr | -0.11 Cr | — |
| Cash Dividends Paid | -0.77 Cr | -0.72 Cr | -0.66 Cr | -0.32 Cr | — |
| Investing Cash Flow | -0.19 Cr | -1.31 Cr | 0.54 Cr | -5.47 Cr | — |
| Net Other Investing Changes | -1000.00 | — | 1000.00 | 1000.00 | -1000.00 |
| Interest Received Cfi | 0.11 Cr | 0.16 Cr | 0.16 Cr | 0.08 Cr | — |
| Net Investment Purchase And Sale | 0.64 Cr | -0.04 Cr | 1.45 Cr | -4.71 Cr | — |
| Sale Of Investment | 3.44 Cr | 1.02 Cr | 1.85 Cr | 5.80 Cr | — |
| Purchase Of Investment | -2.80 Cr | -1.06 Cr | -0.40 Cr | -10.51 Cr | — |
| Net PPE Purchase And Sale | -0.94 Cr | -1.43 Cr | -1.07 Cr | -0.84 Cr | — |
| Purchase Of PPE | -0.94 Cr | -1.43 Cr | -1.07 Cr | -0.84 Cr | — |
| Operating Cash Flow | 0.95 Cr | 0.76 Cr | 0.22 Cr | 0.95 Cr | — |
| Taxes Refund Paid | -0.58 Cr | -0.50 Cr | -0.70 Cr | -0.88 Cr | — |
| Change In Working Capital | -1.32 Cr | -1.22 Cr | -1.77 Cr | -1.13 Cr | — |
| Change In Other Current Liabilities | 0.51 Cr | 0.37 Cr | 0.63 Cr | -1.51 Cr | — |
| Change In Other Current Assets | -0.18 Cr | 0.65 Cr | -0.10 Cr | -0.95 Cr | — |
| Change In Payable | 0.29 Cr | -4.21 Cr | 1.58 Cr | 0.15 Cr | — |
| Change In Inventory | -1.90 Cr | 2.08 Cr | -3.05 Cr | -0.13 Cr | — |
| Change In Receivables | -0.05 Cr | -0.12 Cr | -0.84 Cr | 1.32 Cr | — |
| Other Non Cash Items | -72000.00 | -0.10 Cr | -0.08 Cr | 0.03 Cr | — |
| Provisionand Write Offof Assets | 0.16 Cr | 0.04 Cr | 0.04 Cr | 0.04 Cr | — |
| Depreciation And Amortization | 0.67 Cr | 0.58 Cr | 0.52 Cr | 0.53 Cr | — |
| Depreciation | 0.67 Cr | 0.58 Cr | 0.52 Cr | 0.53 Cr | — |
| Pension And Employee Benefit Expense | -0.13 Cr | -0.12 Cr | 20000.00 | 0.04 Cr | — |
| Net Income From Continuing Operations | 2.16 Cr | 2.07 Cr | 2.22 Cr | 2.32 Cr | — |
| Repurchase Of Capital Stock | — | -0.72 Cr | -0.66 Cr | — | — |
| Repayment Of Debt | — | 0.00 | 0.00 | -0.02 Cr | -1.23 Cr |
| Issuance Of Debt | — | 0.06 Cr | — | — | — |
| Issuance Of Capital Stock | — | 0.00 | 1.32 Cr | 1.38 Cr | 1.74 Cr |
| Net Other Financing Charges | — | -1000.00 | 1.32 Cr | — | 0.90 Cr |
| Net Common Stock Issuance | — | -0.72 Cr | -0.66 Cr | 1.38 Cr | 1.74 Cr |
| Common Stock Payments | — | -0.72 Cr | -0.66 Cr | — | — |
| Common Stock Issuance | — | 0.00 | 1.32 Cr | 1.38 Cr | 1.74 Cr |
| Net Issuance Payments Of Debt | — | 0.06 Cr | 0.00 | -0.02 Cr | -1.23 Cr |
| Net Short Term Debt Issuance | — | 0.06 Cr | 0.00 | -0.02 Cr | -1.23 Cr |
| Short Term Debt Issuance | — | 0.06 Cr | — | — | — |
| Net Long Term Debt Issuance | — | 0.00 | — | — | 0.00 |
| Long Term Debt Payments | — | 0.00 | — | — | 0.00 |
| Dividends Received Cfi | — | 0.16 Cr | 0.00 | 60000.00 | 46000.00 |
| Short Term Debt Payments | — | — | 0.00 | -0.02 Cr | -1.23 Cr |
| Gain Loss On Investment Securities | — | — | — | -60000.00 | -46000.00 |
| Amortization Cash Flow | — | — | — | — | 0.03 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sandu Pharmaceuticals, Inc
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.